Hyderabad-based Indian Immunologicals Limited (IIL) on Friday announced the launch of the pediatric dose of India’s first indigenous Hepatitis A vaccine, Havisure (0.5 ml).
This launch marks a significant milestone in IIL’s ongoing commitment to providing affordable and effective vaccines for all, especially for the most vulnerable sections of society, particularly children, the company said in a statement.
Hepatitis A is a highly contagious liver infection caused by the Hepatitis A virus, which predominantly affects children and can lead to severe health complications. Vaccination is the most cost effective yet efficient method to prevent the disease.
“We are delighted to introduce the pediatric dose of Havisure, the first indigenously developed Hepatitis A vaccine in India. IIL is the single largest contributor to the self-sufficiency of vaccines in the country, this launch is a testament to IIL’s unwavering dedication to innovation and public health. As we celebrate Teachers’ Day, we are reminded of shaping a brighter future for children. We are confident that this vaccine will contribute to a brighter and healthier future for our younger generation. IIL’s endeavor to make indigenous vaccines will give necessary impetus to “Make in India” efforts,” Dr. K. Anand Kumar, Managing Director of Indian Immunologicals Limited, said.
The launch of Havisure reinforces IIL’s long-standing commitment to innovation and public health, solidifying its position as the only company in India to develop an indigenous Hepatitis A vaccine, available in both 0.5 ml and 1 ml dosage forms for pediatric and adult use, respectively, it added.
